D. E. Shaw & Co., Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 47,300 shares of ARWR stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,300

Previous 21,600 118.98%

Holding current value

$1.82 Million

Previous $275,000 171.64%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $964,048 - $1.41 Million	45,474 New	45,474 $1.39 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $20,807 - $34,221	827 Added 2.71%	31,390 $1.12 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $723,731 - $1.18 Million	30,563 New	30,563 $776,000
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $227,572 - $414,445	8,189 New	8,189 $288,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $1.31 Million - $2.32 Million	-33,117 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $510,553 - $725,180	-8,789 Reduced 20.97%	33,117 $2.2 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $1.08 Million - $1.57 Million	-18,506 Reduced 30.63%	41,906 $2.62 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $1.01 Million - $1.47 Million	16,227 Added 36.73%	60,412 $5 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $2.72 Million - $4.02 Million	-44,414 Reduced 50.13%	44,185 $2.93 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $7.64 Million - $14.9 Million	-174,373 Reduced 66.31%	88,599 $6.8 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $5.66 Million - $8.74 Million	-170,546 Reduced 39.34%	262,972 $11.3 Million
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $6.34 Million - $10.5 Million	-242,603 Reduced 35.88%	433,518 $18.7 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $344,873 - $1.06 Million	-16,774 Reduced 2.42%	676,121 $19.5 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $1.22 Million - $3.16 Million	-43,341 Reduced 5.89%	692,895 $44 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $7.42 Million - $9.85 Million	282,631 Added 62.31%	736,236 $20.7 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $1.49 Million - $2.47 Million	-85,553 Reduced 15.87%	453,605 $12 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $6 Million - $10 Million	497,972 Added 1209.08%	539,158 $9.89 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $290,742 - $533,298	-27,071 Reduced 39.66%	41,186 $512,000
Q3 2018 Nov 14, 2018	SELL	$14.0 - $20.3 $639,128 - $926,735	-45,652 Reduced 40.08%	68,257 $1.31 Million
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $4.96 Million - $10.9 Million	-777,875 Reduced 87.23%	113,909 $1.55 Million
Q1 2018 May 15, 2018	SELL	$3.72 - $7.64 $1.03 Million - $2.11 Million	-276,095 Reduced 23.64%	891,784 $6.43 Million
Q4 2017 Feb 14, 2018	BUY	$3.14 - $4.5 $615,788 - $882,499	196,111 Added 20.18%	1,167,879 $4.3 Million
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $1.64 Million - $4.21 Million	971,768	971,768 $4.21 Million

Others Institutions Holding ARWR

# of Institutions

324

Shares Held

99.5M

Call Options Held

444K

Put Options Held

568K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $4.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account